Delving into the Latest Updates on mRNA COVID-19 Vaccine(LiveRNA Therapeutics Inc.) with Synapse

Overview

Basic Info

Drug Type

Prophylactic vaccine, mRNA vaccine

Synonyms

SARS-CoV-2 mRNA Vaccine, mRNA COVID-19 Vaccine(AIM Vaccine), mRNA新冠疫苗（艾美疫苗）

+ [2]

Target

SARS-CoV-2 S protein

Action

inhibitors

Mechanism

SARS-CoV-2 S protein inhibitors(SARS-CoV-2 S protein inhibitors)

Therapeutic Areas

Infectious DiseasesRespiratory DiseasesOther Diseases

Active Indication

COVID-19Severe Acute Respiratory Syndrome

Inactive Indication-

Originator Organization

LiveRNA Therapeutics Inc.

Active Organization

AIM Vaccine Co., Ltd.

Inactive Organization-

License Organization

LiveRNA Therapeutics Inc.

AIM Vaccine Co., Ltd.

Drug Highest PhasePhase 3

First Approval Date-

Regulation-

Login to view timeline

Author: Tomas-Grau, Rodrigo Hernán ; Pingitore, Esteban Vera ; Soliz-Santander, Silvana Estefanía ; Pera, Mariana ; Socias, Sergio Benjamín ; Leguizamón, María Lilia ; Cazorla, Silvia Inés ; Bertolaccini, María Constanza ; Barbaglia, Ana Lucía ; Ávila, César Luis ; Corbalan, Paula María ; Lucero, Luciana González ; Espasa, Gabriela Vanesa ; Ploper, Diego ; Maldonado-Galdeano, Carolina ; Sueldo, Héctor Raúl ; Bellomio, Verónica Inés ; Chehín, Rosana Nieves

BACKGROUNDPatients with autoimmune rheumatic diseases (ARD) are at increased risk of infection due to their impaired immune response, which also reduces vaccination efficacy. Although several studies have evaluated the serological response to SARS-CoV-2 mRNA-based vaccines in patients with ARD, limited information on immune responses to other vaccination platforms is available.AIMSThis observational prospective study aims to investigate the humoral immune response to different SARS-CoV-2 vaccines in patients with ARD.METHODSTotal 66 patients with ARD who were scheduled to receive any SARS-CoV-2 vaccine (Gam-COVID-Vac; AZD1222; BBIBP-CorV; mRNA-1273; BNT162b2 and Ad5-nCoV) were enrolled in the study. We analyzed the humoral immune response elicited against the spike receptor-binding-domain (RBD) of SARS-CoV-2 at 0 and 14 ± 2 d after the first vaccine dose and at 0 ± 1, 21-45, and 180 d after the second one. Titers were also measured in patients who received an additional dose of vaccine.RESULTSAfter the second dose of the vaccine, 70.5% experienced seroconversion. The type of vaccine affected serological responses. BBIBP-CorV resulted in lower seroconversion rates, while mixed vaccinations increased anti-RBD titers. Other factors impacting seroconversion were higher prednisone doses, biological therapy, and hypertension. Patients treated with Rituximab had the lowest seroconversion rate. Regression analysis revealed an 89.0% lower probability of seroconversion for BBIBP-CorV recipients and an 88.0% lower probability for those with hypertension. An additional dose increased seroconversion to 85.7%.CONCLUSIONSTwo-dose vaccination schemes exhibited a 70.5% seroconversion rate to the SARS-CoV-2 vaccine. An additional dose increased this rate to 85.0%. Reduced humoral immune responses were associated with BBIBP-CorV, prednisone higher doses, and biological therapy.

01 Mar 2025·eBioMedicine

Longitudinal immunogenicity cohort study of SARS-CoV-2 mRNA vaccines across individuals with different immunocompromising conditions: heterogeneity in the immune response and crucial role of Omicron-adapted booster doses

Article

Author: Pastore, Gabiria ; Sicuranza, Anna ; Bucalossi, Alessandro ; Montagnani, Francesca ; Tozzi, Monica ; Panza, Francesca ; Lucchesi, Simone ; Ciabattini, Annalisa ; Bennett, David ; Pettini, Elena ; Polvere, Jacopo ; Bocchia, Monica ; Medaglini, Donata ; Fabbiani, Massimiliano ; Garosi, Guido ; Lippi, Arianna ; Bernazzali, Sonia ; Coppola, Chiara ; Costagli, Simone ; Fiorino, Fabio

BACKGROUNDIndividuals with primary and secondary immunodeficiencies, being more susceptible to infections, are a priority for vaccination. Here, we determined and compared in a longitudinal study the immune response elicited by SARS-CoV-2 vaccination across different groups of individuals who are immunocompromised.METHODSIn the PatoVac_COV longitudinal prospective single-centre study, the spike-specific B cell and antibody responses to SARS-CoV-2 mRNA vaccination were compared across 5 different groups of individuals with haematological malignancies, hematopoietic stem cell (HCT) or solid organ transplantation (SOT), undergoing haemodialysis, and people living with HIV (PLWH), for a total of 585 participants. Data from participants who were immunocompromised were compared to a group of 123 participants who were immunocompetent. Blood samples were collected before and after each vaccine administration, up to 2 years.FINDINGSA different immune responsiveness was observed after the first two vaccine doses, with haematological, haemodialysis, and SOT participants showing reduced responsiveness compared to HCT and PLWH, and relative to the comparison group. Spike-specific B cell response was both slower and lower in all groups except in PLWH when compared to participants who were immunocompetent. However, the first booster dose enhanced both the B and the antibody responses in all groups, that persisted up to 2 years after the first vaccine administration. The administration of Omicron-adapted booster vaccines promoted a primary BA.2 RBD-specific B cell response, especially in participants who were immunocompromised. Despite repeated vaccinations, a subset of persistent low-responders, especially among SOT, was identified.INTERPRETATIONOur study highlights the heterogeneous immune response across individuals with different pathologies, the pivotal role of the first booster dose, the primary activation of Omicron-specific B cells elicited by updated variant-adapted vaccines and the persistence of low-responders despite multiple vaccine administrations. These aspects have a clinical relevance for planning vaccination schedules tailored for individuals with different immunocompromising conditions.FUNDINGThis work was supported by funds from the Department of Medical Biotechnologies of the University of Siena, and from EU within the NextGenerationEU-MUR PNRR Tuscany Health Ecosystem (Project no ECS00000017-THE).

24 Feb 2025·JCI Insight

Randomized trial of same- versus opposite-arm coadministration of inactivated influenza and SARS-CoV-2 mRNA vaccines

Article

Author: Kent, Stephen J ; Cromer, Deborah ; Rockman, Steven ; Wheatley, Adam K ; Koutsakos, Marios ; Vu, Mai Ngoc ; Audsley, Jennifer ; Khoury, David S ; Selva, Kevin J ; Reynaldi, Arnold ; Barr, Ian ; Chung, Amy W ; Peck, Heidi ; Juno, Jennifer A ; Lee, Wen Shi ; Tan, Hyon-Xhi ; Kent, Helen E ; Schlub, Timothy E ; Davenport, Miles P ; Zheng, Ming Zm ; Aban, Malet

BACKGROUNDThe immunogenicity of current influenza vaccines needs improvement. Inactivated influenza and COVID-19 mRNA vaccines can be coadministered, but randomized controlled trial data are lacking on whether the 2 vaccines are more immunogenic if given in the same arm or opposite arms. Murine studies suggest mRNA vaccines can adjuvant influenza vaccines when coformulated and codelivered.METHODSWe randomly assigned 56 adults to receive the Afluria quadrivalent inactivated influenza and Moderna monovalent SARS-CoV-2 XBB.1.5 mRNA vaccines, either in opposite arms or both in the same arm at the same site. The primary endpoint was the difference in median combined serum hemagglutination inhibition titer to the H1, H3, and B-Vic vaccine influenza strains after vaccination.RESULTSWe found no significant difference in hemagglutination inhibition antibody levels between the groups (P = 0.30), with the same-arm group having a 1.26-fold higher titer than the opposite-arm group. There were no differences in analyses of antibodies against individual influenza strains or in nasal or saliva antibody levels. While both binding and neutralizing antibody titers against SARS-CoV-2 were not significantly different between groups postvaccination, there was a higher fold-change in BA.5 and ancestral strain neutralizing antibodies in the opposite-arm group.CONCLUSIONInfluenza vaccination is equivalently immunogenic if given in the same arm or opposite arms as the SARS-CoV-2 vaccine, but it may be preferable to administer the SARS-CoV-2 vaccine at a different site from influenza vaccines.TRIAL REGISTRATIONAustralian New Zealand Clinical Trials Registry ACTRN12624000445572.FUNDINGAustralian National Health and Medical Research Council, Australian Medical Research Future Fund, and National Institutes of Health (UH2AI176172).

1

News (Medical) associated with mRNA COVID-19 Vaccine(LiveRNA Therapeutics Inc.)

01 Jun 2021

·en.aimbio.com

AIM Vaccine completed acquisition of Lifanda to accelerate deployment of mRNA COVID-19 Vaccine

On May 31, AIM Vaccine Co., Ltd completed acquisition of Zhuhai Lifanda Biology Co., Ltd, holding 50.1546% of its shares. Lifanda Biology is one of 3 enterprises obtained clinical approval of mRNA COVID-19 vaccine. Such acquisition serves as the integration between manufacturing enterprise and R&D company, which has accelerated R&D and production layout of AIM Vaccine for mRNA vaccine as well as industrialization of technologies of Lifanda Biology on mRNA. This has promoted production and marketing of mRNA COVID-19 vaccine in China. mRNA COVID-19 vaccine as developed by Lifanda Biology obtained Approval Form of Clinical Trial as approved and issued by National Medical Products Administration in March of this year for formal clinical test as scheduled. Since formal input for R&D of mRNA products in 2017, Lifanda Biology has established its own mRNA production and drug delivery technical platform, and has successfully applied numerous patents of invention for drug design, production and delivery of preparations.

VaccineAcquisitionmRNADrug ApprovalClinical Study

100 Deals associated with mRNA COVID-19 Vaccine(LiveRNA Therapeutics Inc.)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Severe Acute Respiratory Syndrome	Phase 3	Kenya	AIM Vaccine Co., Ltd.	30 Jan 2023
COVID-19	Phase 3	China	AIM Vaccine Co., Ltd.	08 Apr 2022

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


EULAR2023	Not Applicable	Systemic Lupus Erythematosus neutralizing antibodies \| SLEDAI \| anti-dsDNA antibodies ... View more	-	SARS-COV-2 MRNA VACCINATION (BNT162b2)	(nqqkkejcgl) = lfhrwqbozd pwzwhfmnnr (wyvvchgfnl ) View more	-	31 May 2023
				SARS-COV-2 MRNA VACCINATION (mRNA-1273)	(qiaqjqigmh) = ltblyslljs vnnidkzcuw (ddbewkvapa )
ACTRIMS2023	Not Applicable	Multiple sclerosis relapse	-	Evobrutinib 75 mg twice-daily	jiorrwjrbu(xajdeupxgp) = yqqawulrdh cvncdvdwrh (ffmrozccmr, 4.5)	-	30 May 2023
				mRNA COVID-19 vaccine	jiorrwjrbu(xajdeupxgp) = jmepktnnvw cvncdvdwrh (ffmrozccmr, 4.3)
ASN2022	Not Applicable	Maintenance	-	SARS-CoV-2 mRNA Vaccines (One dose)	rtwmjopyeq(qxwwzrgtwc) = bkqrkfqjih hiqlwhwdki (uyjkaemlwz, 97 - 100) View more	Positive	05 Nov 2022
				SARS-CoV-2 mRNA Vaccines (Two doses)	rtwmjopyeq(qxwwzrgtwc) = ypygchmefv hiqlwhwdki (uyjkaemlwz, 47 - 76) View more
ASN2022	Not Applicable	Hemodialysis complication	-	mRNA COVID-19 Vaccine (mRNA-1273 (Moderna))	(ilsaspmsbl) = epyhqcfecl kdpwujizin (bdjsazqfwr )	Positive	03 Nov 2022
				BNT-162b2 (Pfizer)	(ilsaspmsbl) = zgwsfrjvqk kdpwujizin (bdjsazqfwr )
NCT05352867 (NEWS) Manual	Phase 2	COVID-19	-	LVRNA009 (成人中剂量组)	(bisypoexiq) = 整体上与疫苗接种有关的不良反应以1级为主，无相关的严重不良事件（SAE）或特殊关注的不良事件，疫苗安全风险低 qdkudgbpok (qihjadxdgu )	Positive	24 Aug 2022
				LVRNA009 (成人高剂量组)
EASL2022	Not Applicable	-	136	mRNA COVID-19 vaccine (Liver transplant patients)	lkgdietsiz(uhtcqhdidx) = xilefxmlkm wfosmhdexu (lwxtekojow, 38.2 - 96.2)	Positive	23 Jun 2022
				Pfizer vaccine	lkgdietsiz(uhtcqhdidx) = jguezprxdl wfosmhdexu (lwxtekojow, 26.4 - 98.9)